GlobeNewswire
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
📈
AI Sentiment
Highly Positive
9/10
- Home
- CYTK
as of 03-16-2026 3:44pm EST
$60.52
+$0.46
+0.77%
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 7.6B | IPO Year: | 2004 |
| Target Price: | $87.56 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.54 | EPS Growth: | -24.33 |
| 52 Week Low/High: | $29.31 - $70.98 | Next Earning Date: | 05-25-2026 |
| Revenue: | $13,368,000 | Revenue Growth: | -87.44% |
| Revenue Growth (this year): | 9.79% | Revenue Growth (next year): | 302.66% |
| P/E Ratio: | -9.18 | Index: | N/A |
| Free Cash Flow: | -534816000.0 | FCF Growth: | N/A |
AI-Powered CYTK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 64.07%
64.07%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cytokinetics Incorporated (CYTK)
Malik Fady Ibraham
Sell
EVP Research & Development
CYTK Mar 9, 2026
Avg Cost/Share
$60.72
Shares
2,907
Total Value
$176,513.04
Owned After
138,629
SEC Form 4
Callos Andrew
Sell
EVP, Chief Commercial Officer
CYTK Mar 9, 2026
Avg Cost/Share
$60.72
Shares
2,582
Total Value
$156,779.04
Owned After
47,858
SEC Form 4
Blum Robert I
Sell
President & CEO
CYTK Mar 9, 2026
Avg Cost/Share
$60.72
Shares
7,931
Total Value
$481,570.32
Owned After
391,673
SEC Form 4
Callos Andrew
Sell
EVP, Chief Commercial Officer
CYTK Mar 5, 2026
Avg Cost/Share
$61.88
Shares
26,000
Total Value
$1,608,730.00
Owned After
47,858
Callos Andrew
Sell
EVP, Chief Commercial Officer
CYTK Mar 2, 2026
Avg Cost/Share
$61.62
Shares
886
Total Value
$54,595.32
Owned After
47,858
SEC Form 4
PARSHALL B LYNNE
Sell
Director
CYTK Mar 2, 2026
Avg Cost/Share
$61.21
Shares
5,000
Total Value
$306,050.00
Owned After
17,933
SEC Form 4
Callos Andrew
Sell
EVP, Chief Commercial Officer
CYTK Feb 5, 2026
Avg Cost/Share
$61.93
Shares
15,000
Total Value
$928,950.00
Owned After
47,858
SEC Form 4
Callos Andrew
Sell
EVP, Chief Commercial Officer
CYTK Feb 2, 2026
Avg Cost/Share
$62.10
Shares
886
Total Value
$55,020.60
Owned After
47,858
SEC Form 4
Callos Andrew
Sell
EVP, Chief Commercial Officer
CYTK Jan 5, 2026
Avg Cost/Share
$60.28
Shares
15,000
Total Value
$904,200.00
Owned After
47,858
SEC Form 4
Callos Andrew
Sell
EVP, Chief Commercial Officer
CYTK Dec 29, 2025
Avg Cost/Share
$62.44
Shares
1,809
Total Value
$112,953.96
Owned After
47,858
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | CYTK | EVP Research & Development | Mar 9, 2026 | Sell | $60.72 | 2,907 | $176,513.04 | 138,629 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Mar 9, 2026 | Sell | $60.72 | 2,582 | $156,779.04 | 47,858 | |
| Blum Robert I | CYTK | President & CEO | Mar 9, 2026 | Sell | $60.72 | 7,931 | $481,570.32 | 391,673 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Mar 5, 2026 | Sell | $61.88 | 26,000 | $1,608,730.00 | 47,858 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Mar 2, 2026 | Sell | $61.62 | 886 | $54,595.32 | 47,858 | |
| PARSHALL B LYNNE | CYTK | Director | Mar 2, 2026 | Sell | $61.21 | 5,000 | $306,050.00 | 17,933 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Feb 5, 2026 | Sell | $61.93 | 15,000 | $928,950.00 | 47,858 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Feb 2, 2026 | Sell | $62.10 | 886 | $55,020.60 | 47,858 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Jan 5, 2026 | Sell | $60.28 | 15,000 | $904,200.00 | 47,858 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Dec 29, 2025 | Sell | $62.44 | 1,809 | $112,953.96 | 47,858 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 24, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 24, 2026 · 100% conf.
AI Prediction SELL
1D
-2.21%
$68.50
5D
-6.42%
$65.55
20D
-7.77%
$64.61
Price: $70.05 Prob +5D: 0% AUC: 1.000
0001193125-26-067012
8-K
0001061983false00010619832026-02-242026-02-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2026
Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter)
Delaware
000-50633
94-3291317
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
350 Oyster Point Boulevard
South San Francisco, California
94080
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 624-3000
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
CYTK
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 24, 2026, Cytokinetics, Incorporated announced its financial results for the fourth quarter and year ended December 31, 2025. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02 and under Exhibit 99.1 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
99.1 Press Release dated February 24, 2026 104 The cover page of this report has been formatted in Inline XBRL
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CYTOKINETICS, INCORPORATED
Date:
February 24, 2026
By:
/s/ John O. Faurescu
SVP, Deputy General Counsel & Secretary
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0001193125-25-266842
8-K
false000106198300010619832025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 05, 2025
Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter)
Delaware
000-50633
94-3291317
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
350 Oyster Point Boulevard
South San Francisco, California
94080
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 624-3000
n/a
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
CYTK
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 5, 2025, Cytokinetics, Incorporated announced its financial results for the third quarter ended September 30, 2025. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02 and under Exhibit 99.1 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein. Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release dated November 5, 2025 104 The cover page of this report has been formatted in Inline XBRL
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CYTOKINETICS, INCORPORATED
Date:
November 5, 2025
By:
/s/ John O. Faurescu
John O. Faurescu SVP, Deputy General Counsel & Secretary
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0000950170-25-104962
8-K
false000106198300010619832025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 07, 2025
Cytokinetics, Incorporated (Exact name of Registrant as Specified in Its Charter)
Delaware
000-50633
94-3291317
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
350 Oyster Point Boulevard
South San Francisco, California
94080
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 624-3000
n/a
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
CYTK
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Cytokinetics, Incorporated announced its financial results for the second quarter ended June 30, 2025. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02 and under Exhibit 99.1 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
99.1 Press Release dated August 7, 2025 104 The cover page of this report has been formatted in Inline XBRL
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CYTOKINETICS, INCORPORATED
Date:
August 7, 2025
By:
/s/ John O. Faurescu
John O. Faurescu, Esq. Vice President, Associate General Counsel & Secretary
Latest Cytokinetics Incorporated News
CYTK Breaking Stock News: Dive into CYTK Ticker-Specific Updates for Smart Investing
MarketBeat
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab
📈
AI Sentiment
Highly Positive
8/10
MarketBeat
Cytokinetics Teases Q2 ACACIA-HCM Catalyst as MYQORZO Launch Gains Momentum at Leerink Conference
📈
AI Sentiment
Highly Positive
9/10
Compare CYTK vs Leading Stocks
See how CYTK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CYTK Cytokinetics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.